Date Time Nutromics wins best early-stage project award Nutromics took home the coverted ‘Best Translational Research’ award at AusMedtech 2021’s Early-Stage Investment Forum, after winning the pitching event judged by an expert investment panel. Nutromics’ Head of Commercial and Intellectual Property Ms Rosie Stramandinoli presented the company’s wearable Continuous Molecular Monitoring (CMM) platform which can measure a wide array of molecular targets continuously and in real time, including drugs, hormones, metabolites, and proteins. This platform technology enables clinicians to receive continuous real-time molecular data to accurately dose a patient and keep them within a narrow therapeutic range. Nutromics’ vision is to create a world with zero preventable deaths due to the lack of timely, molecular-level data.